Navigation Links
Lexicon to Present at BIO International Convention
Date:4/28/2010

ch team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in L
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015  BC Technical, the nation,s ... acquired Eclipse Systems, a Nuclear Imaging service company ... part of their ongoing vision to provide the ... rate, BC Technical continues to expand their reach ... to add valuable resources and knowledge in addition ...
(Date:3/2/2015)... Calif. , March 2, 2015  DURECT ... its Epigenomic Regulator Program, and the successful completion ... program,s lead product candidate DUR-928.  DUR-928 is an ... have broad applicability in metabolic diseases such as ... (NASH), and in acute organ injuries such as ...
(Date:3/2/2015)... -- Intrexon Corporation (NYSE: XON ), a ... quarter and full year results for 2014.  ... , Acquired ActoGeniX, a European clinical stage biopharmaceutical ... and other innovative products.  Its proprietary TopAct™ platform ... Lactococcus lactis ) to generate biologically-contained ActoBiotics™ for ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... 14, 2012  The Consumer Healthcare Products Association (CHPA) ... into law House Bill 2263—anti-meth legislation authored by ... 23rd state to adopt real-time, stop-sale technology known ... The proven system—in a process similar ...
... SCHLIEREN-ZURICH, Switzerland, May 14, 2012 The ALS ... it has entered into collaboration with Neurotune ... Neuron or Lou Gehrig,s disease). (Photo: ... "Maintaining the health of motor neurons ...
Cached Medicine Technology:CHPA Applauds Arizona's Adoption Of HB 2263 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3
(Date:3/2/2015)... Today at the State Capitol, Assemblymember ... the California Healthcare Institute (CHI) and the National ... resolution recognizing Feb. 28, 2015 as Rare Disease ... for millions of Californians living with nearly 7,000 ... research organization, representing leading California academic institutions, biotechnology, ...
(Date:3/2/2015)... the Brain Injury Association of America (BIAA) officially kicked off ... the more than 5.3 million Americans who are living with ... in observing Brain Injury Awareness Month by conducting an awareness ... 2015 to 2017 campaign is: Not Alone. , The ... public about the incidence of brain injury and the needs ...
(Date:3/2/2015)... March 02, 2015 A cocaine ... deviating from the typical nip slip or scathing scuffle. ... industry is dawning the streets of Hollywood as Paper ... about drug addiction and substance abuse in Hollywood. The ... to take a political stance on the travails of ...
(Date:3/2/2015)... “ Wants and Needs ” was ... which features the latest and coolest mobile applications on ... mobile technology expert and host of NewsWatch, conducted the ... helps people evaluate priorities. , Whether a person needs ... Needs app. The app allows people to enter and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 ZoomCare ... to remake American healthcare. Zoom will expand its ... neighborhood clinics and advanced care studios delivering urgent ... emergency services, specialty care and outpatient surgery. With ... access to almost all healthcare needs outside of ...
Breaking Medicine News(10 mins):Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 3Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3
... cancers who receive radical chemoradiation have significantly better ... when compared with patients who have undergone a ... a study in the February 1 issue of ... journal of the American Society for Therapeutic Radiology ...
... The Obesity Action,Coalition (OAC) is calling on the ... 282 (HB 282) that discriminates,against those affected by obesity ... strongly feels that HB 282 is outright discrimination,against the ... attempts,proposed to address the obesity epidemic., Introduced in ...
... play in society, they remain among the most threatened ecosystems ... healthy wetlands for humans, the theme of this years World ... Wetlands, Healthy People. , According to the Ramsar Convention on ... more than 3 million people every year and brings suffering ...
... dance lessons, screenings offered to encourage healthy hearts, ... Month, and Baltimore Washington Medical Center has the key,to ... ), The medical center will host the fourth ... 2008 from 10 a.m. to 3 p.m. at the ...
... of the common Black Rat (Rattus rattus) has shed ... diseases around the globe. , Studying the mitochondrial DNA ... the world, an international team of scientists has identified ... each originating from a different part of Asia. , ...
... Dividend Provides An Annualized Yield Of 9.5%, LARGO, ... Board: UVICF) (TSX Venture Exchange: UVI) Board of Directors,today ... per common,share, payable February 28, 2008 to stockholders of ... "We are pleased to continue the quarterly dividend ...
Cached Medicine News:Health News:Larynx preservation preferred over total laryngectomy 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:Connection between health of wetlands and humans in focus 2Health News:Connection between health of wetlands and humans in focus 3Health News:Baltimore Washington Medical Center Hosts Day of Dance for Health 2Health News:Globetrotting black rat genes reveal spread of humans and diseases 2Health News:Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share 2
... Chart Manager information can be input ... are not limited to drop-down lists ... each person to document individually. Patient ... valuable data and communication. All this ...
AllMeds was the first specialty-specific Electronic Medical Record for Orthopaedics. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Ort...
... software It runs over hospital ... PAS systems and some items ... collects data at initial consultation, ... checks, operation, post-op checks, telephone ...
... such as prescription writing, referral letters, chart ... will be ,able to add more appointments ... staff., Based on the exam documentation created ... recommend the appropriate E&M ,code for the ...
Medicine Products: